S&P affirms Hypera

S&P said it affirmed its BB+ global scale and brAAA Brazilian national scale corporate credit ratings on Hypera SA.

The outlook remains stable.

The agency said the affirmation reflects an expectation that Hypera will continue to have solid cash flow generation resulting from its growing pipeline of new drugs launching, the consistent maturation of its existing branded prescription portfolio and its strict control of costs and expenses.

“These factors should enable its profitability to remain above the industry average, with an EBITDA margin between 34.5% and 36.5% in the next two years,” S&P said in a news release.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.